Leverkusen, Germany, May 31, 2007- Results from various clinical studies including a pivotal Phase III trial in patients with advanced hepatocellular carcinoma, or primary liver cancer with Nexavar (sorafenib) tablets will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA from June 1 - 5, 2007.
On this occasion a conference call for investors and analysts will be held on June 4, 2007. Starting at around 2:00 p.m. CEST (12:00 noon GMT) live on the Internet, Bayer AG will be broadcasting the speech and discussion of the Investor Conference Call.
A recording of the conference call will be available as from 6:30 p.m. CEST (4:30 p.m. GMT).
The audio transmission and recording can be accessed on these sites:
Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com
If you have any questions, please contact:
Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Ilia Kürten (+49-214-30-35426) Ute Menke (+49-214-30-33021) Judith Nestmann (+49-214-30-66836) Dr. Olaf Weber (+49-214-30-33567)